日本肝癌患者隐匿性乙型肝炎感染的频率和特征。

StephenW

Ann Hepatol. 2018 July - August ,;17(4):596-603. doi: 10.5604/01.3001.0012.0927.
Frequency and Characteristics of Occult Hepatitis B Infection Among Hepatocellular Carcinoma Patients in Japan.
Muto J1, Sugiyama M2, Shirabe K1, Mukaide M2, Kirikae-Muto I2, Ikegami T3, Yoshizumi T1, Yamashita YI1, Maehara Y1, Mizokami M2.
Author information

1
    Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
2
    The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
3
    Global Health and Medicine, Ichikawa, Chiba, Japan.

Abstract
INTRODUCTION AND AIM:

Occult hepatitis B virus (HBV) infection (OBI) represents a state without detectable hepatitis B surface antigen, but positive for HBV DNA. The correlation between OBI and hepatocellular carcinoma (HCC) carcinogenesis is controversial. We studied the frequency and characteristics of OBI among HCC patients and metastatic liver cancer patients.
MATERIAL AND METHODS:

DNA was obtained from tumor and non-tumor tissues from 75 HCC patients (15 chronic hepatitis B (CHB), 39 chronic hepatitis C (CHC), 21 cryptogenic) and 15 metastatic liver cancer patients who underwent liver resection. HBV DNA and covalentlyclosed circular (ccc) DNA were detected using real-time polymerase chain reaction (PCR), and four HBV DNA regions were detected by nested PCR. Clinicopathological factors were compared between patients with and without OBI.
RESULTS:

HBV DNA was detected in 14 (93.3%) CHB, five (22.7%) cryptogenic and four (10.3%) CHC patients. cccDNA was detected in 12 (80.0%) CHB, three (14.3%) cryptogenic and two (5.1%) CHC patients. All CHB, eight (38.1%) cryptogenic and ten (25.6%) CHC patients tested positive with nested PCR. No metastatic liver cancer patients were positive for any HBV DNA regions. OBI patients had shorter prothrombin times (P = 0.0055), and lower inflammation activity score in non-tumor liver (P = 0.0274). There were no differences in anti-HBV antibodies.
CONCLUSIONS:

OBI was detected in 38% of cryptogenic and 25.6% of CHC patients. There was no correlation between OBI and anti-HBV antibodies, but fewer patients with OBI had high inflammatory activity, suggesting that factors other than inflammation may be involved in HCC carcinogenesis in patients with OBI.
KEYWORDS:

Hepatocellular carcinoma; Inflammation; Occult hepatitis B virus infection

PMID:
    29893701
DOI:
    10.5604/01.3001.0012.0927

StephenW

安Hepatol。 2018年7月 -  8月，17（4）：596-603。 doi：10.5604 / 01.3001.0012.0927。
日本肝癌患者隐匿性乙型肝炎感染的频率和特征。
Muto J1，Sugiyama M2，Shirabe K1，Mukaide M2，Kirikae-Muto I2，Ikegami T3，Yoshizumi T1，Yamashita YI1，Maehara Y1，Mizokami M2。
作者信息

1
    日本福冈九州大学医学研究科外科学部。
2
    国立全球卫生与医学中心肝炎和免疫研究中心，日本千叶市川市。
3
    Global Health and Medicine，Ichikawa，Chiba，Japan。

抽象
引言和目的：

隐匿性乙型肝炎病毒（HBV）感染（OBI）代表没有可检测的乙型肝炎表面抗原但HBV DNA阳性的状态。 OBI与肝细胞癌（HCC）癌变之间的相关性存在争议。我们研究了HCC患者和转移性肝癌患者中OBI的频率和特征。
材料与方法：

从75例HCC患者（15例慢性乙型肝炎（CHB），39例慢性丙型肝炎（CHC），21例隐源性）和15例接受肝切除的转移性肝癌患者的肿瘤和非肿瘤组织获得DNA。采用实时聚合酶链反应（PCR）检测HBV DNA和共价闭环（ccc）DNA，巢式PCR检测4个HBV DNA区域。比较有或无OBI患者的临床病理因素。
结果：

在14例（93.3％）CHB，5例（22.7％）隐原性和4例（10.3％）CHC患者中检测到HBV DNA。 cccDNA在12例（80.0％）CHB，3例（14.3％）隐原性和2例（5.1％）CHC患者中检测到。所有慢性乙型肝炎，8例（38.1％）隐源性和10例（25.6％）CHC患者用巢式PCR检测为阳性。没有转移性肝癌患者对任何HBV DNA区域都呈阳性。 OBI患者凝血酶原时间缩短（P = 0.0055），非肿瘤肝脏炎症活动评分降低（P = 0.0274）。抗HBV抗体没有差异。
结论：

OBI在38％的隐原性和25.6％的CHC患者中检测到。 OBI与抗-HBV抗体之间无相关性，但较少OBI患者具有较高的炎症活性，提示除了炎症以外的因素可能参与了OBI患者的HCC癌变。
关键词：

肝细胞癌;炎;隐匿性乙型肝炎病毒感染

结论：
    29893701
DOI：
    10.5604 / 01.3001.0012.0927